查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1830985

卵巢癌藥物市場

Ovarian Cancer Drugs Market
出版日期: | 出版商: The Insight Partners | 英文 150 Pages | 商品交期: 1-5個工作天內

價格
簡介目錄

卵巢癌藥物市場預計將從 2024 年的 24.3 億美元擴大到 2031 年的 42.3 億美元，預計 2025 年至 2031 年的複合年成長率為 7.1%。

市場洞察與分析師觀點：卵巢癌發生率的不斷上升推動了卵巢癌藥物市場的成長。然而，由於副作用而導致的產品召回阻礙了市場擴張。

成長催化劑：卵巢癌發生率上升，刺激了對治療方案的需求。卵巢癌是女性第七大常見癌症，也是第三大常見婦科癌症，僅次於子宮頸癌和子宮內膜癌。根據世界卵巢癌聯盟統計，每年有32.4萬名女性被診斷出罹患卵巢癌，其中20.7萬人死於此病。由於缺乏用於早期發現的公共衛生篩檢項目，大多數卵巢癌患者在確診時已是晚期。因此，卵巢癌發生率的上升推動了對有效治療方案的需求。對於新診斷為晚期卵巢癌的女性，標準的第一線治療包括減瘤手術和鉑類化療的組合。此外，已獲批准的PARP抑制劑，如奧拉帕尼、魯卡帕尼和尼拉帕尼，代表了新診斷卵巢癌治療的重大進展。事實證明，使用 PARP 抑制劑是治療晚期卵巢癌的有效策略，可提高臨床效果，並在對初始鉑類化療方案完全緩解 (CR) 後提供長期療效和無惡化存活期 (PFS)。

策略洞察報告細分和範圍：透過檢查以下細分來分析卵巢癌藥物市場：類型、藥物類別和配銷通路。

細分分析：市場依類型分為上皮性卵巢癌、生殖細胞卵巢癌和間質腫瘤。上皮性卵巢癌在2022年佔據了卵巢癌藥物市場的最大佔有率，預計在預測期內將達到8.2%的最高複合年成長率。根據英國癌症研究中心的數據，上皮性卵巢癌是最常見的卵巢癌類型，近90%的卵巢腫瘤本質上是上皮性腫瘤。晚期侵襲性卵巢癌患者的治療選擇有限。 2022年11月，美國食品藥物管理局（FDA）批准了由Elahere ImmunoGen, Inc.開發的“mirvetuximab soravtansine-gynx”，用於治療成人上皮性卵巢癌患者。此藥物的建議劑量為6毫克/公斤，每三週靜脈輸註一次。 2024年1月，FDA授予「RC88」快速通道資格認定（FTD），這是一款針對間皮素的抗體-藥物偶聯物（ADC），旨在治療復發性上皮性卵巢癌患者。因此，越來越多的藥物獲準正在推動卵巢癌藥物市場的成長，尤其是在上皮性卵巢癌領域。

卵巢癌藥物市場趨勢聯合藥物治療眾多醫學研究機構正在研究卵巢癌治療的創新聯合療法。 2023 年 9 月，皇家馬斯登醫院的研究人員宣布了一種新的聯合藥物療法，該療法已顯示出對晚期卵巢癌患者的有效性。這種聯合療法針對低度漿液性卵巢癌 (LGSOC) 進行了影響測試，LGSOC 是一種罕見的卵巢癌，通常對現有治療反應不佳。 RAMP-201 臨床試驗結合了 avutometinib 和 defactinib 兩種藥物，以探索它們對 LGSOC 患者的協同作用。中期結果表明，接受這種聯合治療的患者中有 45% 的腫瘤明顯縮小，幾乎是曲美替尼 (trametinib) 有效性的兩倍，而曲美替尼是一種反應率僅為 26% 的標靶治療藥物。 2024 年 1 月，FDA 批准了 SH-105 聯合藥物用於治療乳癌和卵巢癌患者。因此，聯合藥物療法正在成為一種新趨勢，並可能在未來幾年促進卵巢癌藥物市場的成長。

區域分析：卵巢癌藥物市場報告涵蓋北美、歐洲、亞太地區、南美和中美以及中東和非洲等地區。 2022年，北美佔據了卵巢癌藥物市場的最大佔有率，這得益於領先公司推出的產品數量增加以及主要市場參與者的參與。美國是北美市場的主要貢獻者。女性卵巢癌發生率的上升促使公司和監管機構在該地區開發和批准創新藥物。此外，越來越多的合約臨床研究組織 (CRO) 也支持了北美卵巢癌藥物市場的成長。

卵巢癌藥物市場報告範圍：產業發展與未來機會：卵巢癌藥物市場的預測可以幫助利害關係人規劃其成長策略。以下是一些市場領導企業的策略發展：

2022年11月，ImmunoGen公司獲得美國食品藥物管理局（FDA）批准ELAHERE（mirvetuximab soravtansine-gynx）用於治療鉑類抗藥性的成年上皮性卵巢癌患者。 ELAHERE被專門核准用於治療FRα陽性的鉑類抗藥性卵巢癌患者。由於治療方案有限且現有療法的臨床療效不佳，這種卵巢癌治療具有挑戰性。競爭格局與重點公司：卵巢癌藥物市場報告中介紹的知名公司包括禮來公司、阿斯特捷利康公司、葛蘭素史克公司、Zielab公司、ImmunoGen公司（艾伯維公司）、GeneTech公司（羅氏公司）、Vivesto公司、Allarity Therapeutics公司、Aeterna Zentaris公司和綠葉製藥公司。這些公司專注於開發新技術、改進現有產品並擴大其地域覆蓋範圍，以滿足日益成長的全球需求。

目錄

第1章：簡介

第2章：執行摘要

  • 關鍵見解
  • 市場吸引力分析

第3章：研究方法

第4章：卵巢癌藥物市場格局

  • 概述
  • PEST分析
  • 生態系分析
    • 價值鏈中的供應商列表

第5章：卵巢癌藥物市場－關鍵市場動態

  • 關鍵市場促進因素
  • 主要市場限制因素
  • 關鍵市場機會
  • 未來趨勢
  • 促進因素和限制因素的影響分析

第6章：卵巢癌藥物市場－全球市場分析

  • 卵巢癌藥物－全球市場概覽
  • 卵巢癌藥物－全球市場及2031年預測

第7章：卵巢癌藥物市場-收入分析-按類型，2021-2031

  • 概述
  • 上皮性卵巢癌
  • 生殖細胞卵巢癌
  • 間質腫瘤

第 8 章：卵巢癌藥物市場 - 收入分析 - 按藥物類別，2021-2031 年

  • 概述
  • PARP抑制劑
  • 抗血管新生抑制劑
  • 其他

第9章：卵巢癌藥物市場-收入分析-按配銷通路，2021-2031

  • 概述
  • 醫院藥房
  • 零售藥局
  • 其他

第 10 章：卵巢癌藥物市場 - 收入分析，2021-2031 - 地理分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 英國
    • 歐洲其他地區
  • 亞太
    • 澳洲
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 中東和非洲其他地區
  • 南美洲和中美洲
    • 巴西
    • 阿根廷
    • 南美洲和中美洲其他地區

第 11 章：產業格局

  • 併購
  • 協議、合作、合資企業
  • 新產品發布
  • 擴張和其他策略發展

第 12 章：競爭格局

  • 關鍵參與者的熱圖分析
  • 公司定位與集中度

第 13 章：卵巢癌藥物市場 - 關鍵公司簡介

  • AbbVie Inc
  • AstraZeneca
  • F. Hoffmann-La Roche Ltd
  • Pfizer, Inc.
  • Merck and Co., Inc.
  • ImmunoGen, Inc
  • CLOVIS ONCOLOGY
  • Boehringer Ingelheim International GmbH
  • GlaxoSmithKline, Plc
  • Amgen Inc

第 14 章：附錄

簡介目錄
Product Code: TIPRE00003750

The ovarian cancer drugs market is anticipated to expand from US$ 2.43 billion in 2024 to US$ 4.23 billion by 2031, reflecting a projected CAGR of 7.1% from 2025 to 2031.

Market Insights and Analyst Perspective:The increasing prevalence of ovarian cancer is driving the growth of the ovarian cancer drugs market. However, product recalls due to side effects are hindering market expansion.

Growth Catalysts:Increasing Incidence of Ovarian Cancer Fuels Demand for Treatment Options

Ovarian cancer ranks as the seventh most prevalent cancer among women and the third most common gynecological cancer, following cervical and endometrial cancers. According to the World Ovarian Cancer Coalition, 324,000 women are diagnosed with ovarian cancer each year, with 207,000 fatalities attributed to the disease. Most ovarian cancer patients are diagnosed at an advanced stage due to the absence of public health screening programs for early detection. Consequently, the rising incidence of ovarian cancer drives the need for effective treatment options. The standard first-line treatment for women newly diagnosed with advanced ovarian cancer involves a combination of debulking surgery and platinum-based chemotherapy. Additionally, approved PARP inhibitors such as olaparib, rucaparib, and niraparib represent significant advancements in managing newly diagnosed ovarian cancer. The use of PARP inhibitors has proven to be an effective therapeutic strategy for advanced ovarian cancer, enhancing clinical outcomes and providing long-term efficacy and progression-free survival (PFS) following a complete response (CR) to initial platinum-based chemotherapy regimens.

Strategic Insights

Report Segmentation and Scope:The analysis of the ovarian cancer drugs market has been conducted by examining the following segments: type, drug class, and distribution channel.

Segmental Analysis:The market is categorized by type into epithelial ovarian cancer, germ cell ovarian cancer, and stromal tumors. The epithelial ovarian cancer segment accounted for the largest share of the ovarian cancer drugs market in 2022 and is expected to achieve the highest CAGR of 8.2% during the forecast period. According to Cancer Research UK, epithelial ovarian cancer is the most prevalent form of ovarian cancer, with nearly 90% of ovarian tumors being epithelial in nature. Patients with aggressive, late-stage ovarian cancer face limited treatment options. In November 2022, the FDA approved "mirvetuximab soravtansine-gynx," developed by Elahere ImmunoGen, Inc., for adult patients with epithelial ovarian cancer. The recommended dosage for this drug is 6 mg/kg, administered as an IV infusion every three weeks. In January 2024, the FDA granted fast-track designation (FTD) for "RC88," a mesothelin-targeting antibody-drug conjugate (ADC) aimed at treating patients with recurrent epithelial ovarian cancer. Thus, the increasing number of drug approvals is driving growth in the ovarian cancer drugs market, particularly for the epithelial ovarian cancer segment.

Ovarian Cancer Drugs Market Trends

Combination Drug Therapy

Numerous medical research institutions are working on innovative combination therapies for ovarian cancer treatment. In September 2023, researchers at the Royal Marsden announced a new combination drug therapy that has shown effectiveness in patients with advanced ovarian cancer. This combination therapy was tested for its impact on low-grade serous ovarian cancer (LGSOC), a rare type of ovarian cancer that typically has a poor response to existing treatments. The RAMP-201 clinical trial combined the drugs avutometinib and defactinib to explore their synergistic effects in LGSOC patients. Interim results indicated that 45% of patients treated with this combination experienced significant tumor shrinkage, nearly double the effectiveness of trametinib, a targeted therapy with a response rate of only 26%. In January 2024, the FDA approved the SH-105 combination drug for treating patients with breast and ovarian cancer. Therefore, combination drug therapies are emerging as a new trend likely to enhance growth in the ovarian cancer drugs market in the coming years.

Regional Analysis:The ovarian cancer drugs market report covers regions including North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa. In 2022, North America held the largest share of the ovarian cancer drugs market, driven by an increase in product launches from leading companies and the presence of key market players. The US is the primary contributor to the market in North America. The rising incidence of ovarian cancer among women is prompting companies and regulatory bodies to develop and approve innovative drugs in this region. Additionally, the growing number of contract clinical research organizations (CROs) supports the growth of the ovarian cancer drugs market in North America.

Ovarian Cancer Drugs Market Report ScopeIndustry Developments and Future Opportunities:The forecast for the ovarian cancer drugs market can assist stakeholders in planning their growth strategies. Below are some strategic developments by leading players in the market:

In November 2022, ImmunoGen received FDA approval for ELAHERE (mirvetuximab soravtansine-gynx) to treat adult patients with platinum-resistant epithelial ovarian cancer. ELAHERE is specifically approved for patients with FRα-positive platinum-resistant ovarian cancer, a challenging condition due to limited treatment options and poor clinical outcomes from existing therapies.

Competitive Landscape and Key Companies:Prominent companies profiled in the ovarian cancer drugs market report include Eli Lilly, AstraZeneca, GSK, Zielab, ImmunoGen (AbbVie), GeneTech (Roche), Vivesto, Allarity Therapeutics, Inc., Aeterna Zentaris, and Luye Pharma. These companies are focused on developing new technologies, enhancing existing products, and expanding their geographic reach to meet the growing global demand.

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 Market Definition, Assumptions and Limitations
  • 1.3 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 Market Attractiveness Analysis

3. Research Methodology

4. Ovarian Cancer Drugs Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
  • 4.3 Ecosystem Analysis
    • 4.3.1 List of Vendors in the Value Chain

5. Ovarian Cancer Drugs Market - Key Market Dynamics

  • 5.1 Key Market Drivers
  • 5.2 Key Market Restraints
  • 5.3 Key Market Opportunities
  • 5.4 Future Trends
  • 5.5 Impact Analysis of Drivers and Restraints

6. Ovarian Cancer Drugs Market - Global Market Analysis

  • 6.1 Ovarian Cancer Drugs - Global Market Overview
  • 6.2 Ovarian Cancer Drugs - Global Market and Forecast to 2031

7. Ovarian Cancer Drugs Market - Revenue Analysis (USD Million) - By Type, 2021-2031

  • 7.1 Overview
  • 7.2 Epithelial Ovarian Cancer
  • 7.3 Germ Cell Ovarian Cancer
  • 7.4 Stromal Tumors

8. Ovarian Cancer Drugs Market - Revenue Analysis (USD Million) - By Drug Class, 2021-2031

  • 8.1 Overview
  • 8.2 PARP Inhibitors
  • 8.3 Anti-Angiogenesis Inhibitors
  • 8.4 Others

9. Ovarian Cancer Drugs Market - Revenue Analysis (USD Million) - By Distribution Channel, 2021-2031

  • 9.1 Overview
  • 9.2 Hospital Pharmacies
  • 9.3 Retail Pharmacies
  • 9.4 Others

10. Ovarian Cancer Drugs Market - Revenue Analysis (USD Million), 2021-2031 - Geographical Analysis

  • 10.1 North America
    • 10.1.1 North America Ovarian Cancer Drugs Market Overview
    • 10.1.2 North America Ovarian Cancer Drugs Market Revenue and Forecasts to 2031
    • 10.1.3 North America Ovarian Cancer Drugs Market Revenue and Forecasts and Analysis - By Type
    • 10.1.4 North America Ovarian Cancer Drugs Market Revenue and Forecasts and Analysis - By Drug Class
    • 10.1.5 North America Ovarian Cancer Drugs Market Revenue and Forecasts and Analysis - By Distribution Channel
    • 10.1.6 North America Ovarian Cancer Drugs Market Revenue and Forecasts and Analysis - By Countries
      • 10.1.6.1 United States Ovarian Cancer Drugs Market
        • 10.1.6.1.1 United States Ovarian Cancer Drugs Market, by Type
        • 10.1.6.1.2 United States Ovarian Cancer Drugs Market, by Drug Class
        • 10.1.6.1.3 United States Ovarian Cancer Drugs Market, by Distribution Channel
      • 10.1.6.2 Canada Ovarian Cancer Drugs Market
        • 10.1.6.2.1 Canada Ovarian Cancer Drugs Market, by Type
        • 10.1.6.2.2 Canada Ovarian Cancer Drugs Market, by Drug Class
        • 10.1.6.2.3 Canada Ovarian Cancer Drugs Market, by Distribution Channel
      • 10.1.6.3 Mexico Ovarian Cancer Drugs Market
        • 10.1.6.3.1 Mexico Ovarian Cancer Drugs Market, by Type
        • 10.1.6.3.2 Mexico Ovarian Cancer Drugs Market, by Drug Class
        • 10.1.6.3.3 Mexico Ovarian Cancer Drugs Market, by Distribution Channel
  • 10.2 Europe
    • 10.2.1 Germany
    • 10.2.2 France
    • 10.2.3 Italy
    • 10.2.4 Spain
    • 10.2.5 United Kingdom
    • 10.2.6 Rest of Europe
  • 10.3 Asia-Pacific
    • 10.3.1 Australia
    • 10.3.2 China
    • 10.3.3 India
    • 10.3.4 Japan
    • 10.3.5 South Korea
    • 10.3.6 Rest of Asia-Pacific
  • 10.4 Middle East and Africa
    • 10.4.1 South Africa
    • 10.4.2 Saudi Arabia
    • 10.4.3 U.A.E
    • 10.4.4 Rest of Middle East and Africa
  • 10.5 South and Central America
    • 10.5.1 Brazil
    • 10.5.2 Argentina
    • 10.5.3 Rest of South and Central America

11. Industry Landscape

  • 11.1 Mergers and Acquisitions
  • 11.2 Agreements, Collaborations, Joint Ventures
  • 11.3 New Product Launches
  • 11.4 Expansions and Other Strategic Developments

12. Competitive Landscape

  • 12.1 Heat Map Analysis by Key Players
  • 12.2 Company Positioning and Concentration

13. Ovarian Cancer Drugs Market - Key Company Profiles

  • 13.1 AbbVie Inc
    • 13.1.1 Key Facts
    • 13.1.2 Business Description
    • 13.1.3 Products and Services
    • 13.1.4 Financial Overview
    • 13.1.5 SWOT Analysis
    • 13.1.6 Key Developments
  • 13.2 AstraZeneca
  • 13.3 F. Hoffmann-La Roche Ltd
  • 13.4 Pfizer, Inc.
  • 13.5 Merck and Co., Inc.
  • 13.6 ImmunoGen, Inc
  • 13.7 CLOVIS ONCOLOGY
  • 13.8 Boehringer Ingelheim International GmbH
  • 13.9 GlaxoSmithKline, Plc
  • 13.10 Amgen Inc

14. Appendix

  • 14.1 Glossary
  • 14.2 About The Insight Partners
  • 14.3 Market Intelligence Cloud